New Coronary Pneumonia | Brazil Butantan Institute: The effective rate of Coxing vaccine is only over 50%

Instant International

Written by: Hong Yilin

2021-01-13 02:11

Last update date: 2021-01-13 02:11

The Butantan Institute in Brazil said on January 12 that in a late-stage clinical trial in China, the "overall effective rate" of the new coronavirus pneumonia (COVID-19) vaccine developed by Sinovac in China ( The general efficacy is only 50.4%.

Ricardo Palacios, who is in charge of clinical research at the Brazilian Butantan Institute, which is Coxing’s local partner, said that the new data includes “very mild” infections that do not require treatment.

The authorities stated on the 7th that the "clinical efficacy" of Kexing vaccine was 78%.

In addition to Brazil, many countries around the world have participated in the research on the effectiveness of the vaccine. Turkish researchers announced in December that according to an interim analysis, the vaccine’s effective rate was 91.25%; Indonesian authorities’ data showed that it was 65%, and it was reported on the 11. Grant an emergency license.

However, the Butantan Institute pointed out that the local research was conducted during the most severe situation of the epidemic. The participants included frontline medical staff and elderly volunteers, so it is difficult to compare with other research or vaccines.

One of the three vaccines purchased by the Hong Kong government is Kexing vaccine.

↓If you want to know the lives of people in other countries during the epidemic, please click to enlarge to watch:

New crown pneumonia | Brazil will soon announce the results of Coxing's vaccine test, the media says the effective rate is less than 60%

Covid-19 vaccine | Thailand will allocate more than 300 million yuan to purchase China Kexing vaccine

New crown vaccine | Brazil announced plans to purchase 100 million doses of China Kexing vaccine

The government of Sao Paulo, Brazil: The effective rate of China Kexing vaccine in the local late test is 78%

01News

Brazil vaccine Covid-19 vaccine Covid-19